State Board of Administration of Florida Retirement System lifted its stake in Eli Lilly and Company (NYSE:LLY) by 0.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,426,721 shares of the company’s stock after buying an additional 11,922 shares during the period. State Board of Administration of Florida Retirement System owned about 0.14% of Eli Lilly and worth $122,042,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of LLY. Advantus Capital Management Inc raised its holdings in shares of Eli Lilly and by 0.4% in the 1st quarter. Advantus Capital Management Inc now owns 97,698 shares of the company’s stock worth $8,217,000 after buying an additional 425 shares in the last quarter. Modera Wealth Management LLC acquired a new stake in Eli Lilly and during the 1st quarter valued at $238,000. Partnervest Advisory Services LLC increased its holdings in Eli Lilly and by 12.4% during the 1st quarter. Partnervest Advisory Services LLC now owns 5,820 shares of the company’s stock valued at $489,000 after purchasing an additional 643 shares in the last quarter. Stephens Inc. AR increased its holdings in Eli Lilly and by 4.5% during the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after purchasing an additional 1,901 shares in the last quarter. Finally, Bellevue Group AG increased its holdings in Eli Lilly and by 275.4% during the 1st quarter. Bellevue Group AG now owns 131,400 shares of the company’s stock valued at $11,052,000 after purchasing an additional 96,400 shares in the last quarter. 76.42% of the stock is owned by institutional investors and hedge funds.
Shares of Eli Lilly and Company (LLY) traded up $0.58 on Monday, reaching $86.45. The company’s stock had a trading volume of 3,777,100 shares, compared to its average volume of 3,673,659. Eli Lilly and Company has a 52-week low of $67.22 and a 52-week high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The company has a market cap of $95,189.66, a price-to-earnings ratio of 21.14, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the company earned $0.88 EPS. The firm’s revenue was up 9.0% on a year-over-year basis. equities analysts forecast that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th were given a $0.52 dividend. The ex-dividend date was Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.41%. Eli Lilly and’s dividend payout ratio is currently 98.58%.
LLY has been the subject of a number of recent analyst reports. BMO Capital Markets reaffirmed a “sell” rating and set a $71.00 price target on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Friday, October 13th. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price target (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $90.25.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders sold a total of 628,588 shares of company stock worth $53,399,536 over the last 90 days. 0.20% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://transcriptdaily.com/2017/12/11/state-board-of-administration-of-florida-retirement-system-buys-11922-shares-of-eli-lilly-and-company-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.